Cytori Therapeutics Says Clinical Study Approved in Japan

Cytori Therapeutics

today announced that a 40-patient, multi-center investigator-sponsored and funded clinical study in Japan using the Celution® System has been approved under the Ministry of Health, Labor and Welfare (MHLW) Guidelines on Clinical Research Using Human Stem Cells. The study will investigate the use of patients' own adipose-derived stem and regenerative cells (ADRCs) processed by the Celution® System for peripheral artery disease (PAD) or arteriosclerosis obliterans (AO). PAD or AO are common circulatory problems in which narrowed arteries reduce blood flow to the limbs. The principal investigator will be Toyoaki Murohara, M.D., Ph.D., Professor and Chairman, Department of Cardiology at the primary trial center, Nagoya University Graduate School of Medicine. The trial will include two additional Japanese sites.